George Cardoza bought stock once, on Jun 5, 2026

George Cardoza is a corporate finance and operations executive in the clinical diagnostics and precision medicine industry, known for his leadership roles at NeoGenomics, Inc. and its subsidiaries.( At NeoGenomics, a cancer‑focused genetic testing company, he served as Chief Financial Officer from 2009 to 2018, later becoming President, Pharma Services Division from 2018 to 2021 and President & Chief Operating Officer, Lab Operations from 2021 to 2022, overseeing internal financial affairs and the growth of the company’s pharma services business.( In his role as President, Pharma Services at NeoGenomics, Cardoza led the division’s expansion in clinical trials and pharma-focused testing services, drawing on more than three decades of experience in healthcare diagnostics and corporate finance.(

Before joining NeoGenomics, Cardoza held senior finance positions including Chief Financial Officer at Protocol Global Solutions and Protocol Integrated Direct Marketing, and Controller for the Central Region at Quest Diagnostics, where he was responsible for financial management across multiple major laboratories.( He later advanced to chief executive leadership as CEO and board member of AccuraGen, a biotechnology company focused on liquid biopsy technologies, and subsequently to global finance leadership roles such as CFO and Head of Service Delivery at Biocartis and Chief Financial Officer at SOPHiA GENETICS, where he oversees corporate finance, FP&A, investor relations, and treasury for a data‑driven medicine company.( Cardoza holds a B.S. in Finance and Accounting from Syracuse University and an MBA in Management from Michigan State University’s Eli Broad College of Business, underpinning his long‑standing track record of financial stewardship and operational performance in the life sciences sector.(

Written by Perplexity from public sources.